gdc
PSSGuide_2020
Liver Cancer

Drugs for Liver Cancer

Here are the drugs and financial support services available to patients receiving treatment for Liver Cancer (Hepatocellular Carcinoma).

Cabometyx (cabozantinib)

Drug company: Exelixis
844-900-3273

Cabometyx is a kinase inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) after they received chemotherapy with Nexavar.

Exelixis Access Services offers 3 financial assistance programs for patients using Cabometyx:

EASE Co-pay Program

Patients with private insurance who are eligible for this program will pay $0 per month for Cabometyx, up to a maximum benefit of $25,000 per year.

EASE Quick Start Program

Eligible patients who experience a delay of more than 5 days in the processing or approval of their prescription can receive a 15-day supply of Cabometyx at no cost.

EASE Patient Assistance Program

This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-427-8663

Cyramza is a human VEGF receptor 2 antagonist used as a single therapy for the treatment of hepatocellular carcinoma (liver cancer) in patients who have an alpha fetoprotein of ≥400 ng/mL after they received chemotherapy with Nexavar.

Lilly PatientOne offers 2 financial assistance programs for patients who have been prescribed Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 for a dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $62,450 for 1 person; $84,550 for 2 people; $106,650 for 3 people; $128,750 for 4 people; $150,850 for 5 people; $172,950 for 6 people, this program provides Cyramza at no cost.

Defitelio (defibrotide sodium)

Drug company: Jazz Pharmaceuticals
888-837-4397

Defitelio is used for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a rare and life-threatening liver condition that can occur after hematopoietic stem-cell transplantation in patients with different types of cancers.

Jazz Pharmaceuticals offers 1 financial assistance program for patients using Defitelio:

JumpStart Patient Assistance Program

This program offers Defitelio at no cost for patients who are uninsured or deemed uninsured due to lack of coverage for Defitelio. Program benefits are subject to financial and residency eligibility criteria.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used as the first-line treatment of patients with unresectable (cannot be removed by surgery) hepatocellular carcinoma (liver cancer).

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription of Lenvima, with a $40,000 annual limit.

Eisai Patient Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with unresectable hepatocellular carcinoma (liver cancer).

Bayer offers 2 financial assistance programs for patients using Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay $0 copay for Nexavar, and the program pays up to $25,000 per patient annually

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Nexavar should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication for up to 12 months.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) who have previously received Nexavar.

Bristol-Myers Squibb (BMS) Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) who have received Nexavar.

Bayer offers 2 financial assistance programs for patients using Stivarga:

STIVARGA $0 Co-Pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Table. Drugs Prescribed for Liver Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Defitelio (defibrotide sodium)
  • Drug company
  • Jazz Pharmaceuticals
  • Indication
  • Hepatic veno-occlusive disease (often associated with cancer-related transplant)
  • Patient support services
  • JazzCares Patient Assistance Program
    888-837-4397





Last modified: April 13, 2020